It offers a wide variety of weight-loss drugs, including Zepbound and Ozempic, and her husband, Alexis Ohanian, is an investor in the company, serving on the board
Even if these numbers are accurate (and not the result of the group size differences as I mentioned before) these strike me as pretty big numbers - about half of people have moderate events and somewhere between 8 and 10% are severe
So whether youre using a GLP one medication, considering one, or choosing a different path entirely, the focus stays the same
CagriSema combines two proven mechanisms (amylin + GLP-1) in a fixed-dose injection, achieving 20.4% weight loss in Phase 3, with an NDA already filed and the advantage of building on the well-characterized semaglutide platform
Your provider should assess which delivery method aligns with your preferences, GI health status, and adherence patterns